Cargando…

Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life

BACKGROUND: Brain metastases (BM) represent one of the most frequent complications related to cancer, and their treatment continues to evolve. We have evaluated the activity, toxicity and the impact on Quality of Life (QoL) of a concomitant treatment with whole brain radiotherapy (WBRT) and Temozolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Addeo, Raffaele, Caraglia, Michele, Faiola, Vincenzo, Capasso, Elena, Vincenzi, Bruno, Montella, Liliana, Guarrasi, Rosario, Caserta, Luigi, Del Prete, Salvatore
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794253/ https://www.ncbi.nlm.nih.gov/pubmed/17254350 http://dx.doi.org/10.1186/1471-2407-7-18

Ejemplares similares

Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports
por: Montella, Liliana, et al.
Publicado: (2009)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

TMZ-BioShuttle – a reformulated Temozolomide
por: Waldeck, Waldemar, et al.
Publicado: (2008)

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
por: Lesueur, Paul, et al.
Publicado: (2019)

OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth()()
por: Towner, Rheal A., et al.
Publicado: (2018)

Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis
por: Lu, Fei, et al.
Publicado: (2019)

Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan
por: Lo, Serigne N., et al.
Publicado: (2019)

MLTI-02. A PHASE I TRIAL OF SORAFENIB WITH WHOLE BRAIN RADIOTHERAPY (WBRT) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES AND A CORRELATIVE FLT-PET BRAIN IMAGING STUDY IN PATIENTS RECEIVING WBRT +/- SORAFENIB
por: Morikawa, Aki, et al.
Publicado: (2019)

Efficacy and safety of WBRT+EGFR‐TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: An updated meta‐analysis
por: Zhou, Kai, et al.
Publicado: (2021)

Setup uncertainties and appropriate setup margins in the head-tilted supine position of whole-brain radiotherapy (WBRT)
por: Park, Jae Won, et al.
Publicado: (2022)

Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay
por: Babaloui, Somayyeh, et al.
Publicado: (2022)

Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study
por: Zhen, Junjie, et al.
Publicado: (2020)

Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report
por: Qie, Shuai, et al.
Publicado: (2019)

A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression
por: Shervington, Leroy, et al.
Publicado: (2020)

Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study
por: Addeo, Raffaele, et al.
Publicado: (2019)

SUN-932 Successful Response of Temozolomide (TMZ) in two Patients with Metastatic Pheochromocytoma/Paragangliomas (PPGLs)
por: de Almeida, Tobias Skrebsky, et al.
Publicado: (2020)

LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021)

Comparison between flattening filter‐free (FFF) and flattened photon beam VMAT plans for the whole brain radiotherapy (WBRT) with hippocampus sparing
por: Ji, Tianlong, et al.
Publicado: (2021)

RADI-01. PROGNOSTIC FACTORS OF SHORT SURVIVAL FOR BRAIN METASTASES TREATED WITH SRS WITHOUT WBRT.
por: Harat, Maciej, et al.
Publicado: (2019)

Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells In Vitro by Inhibiting Autophagy
por: Chen, Zhihua, et al.
Publicado: (2022)

miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
por: He, Zongze, et al.
Publicado: (2022)

DIPG-26. THERAPEUTIC EFFECTS OF RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY WITH CONCOMITANT TEMOZOLOMIDE ALONE IN CHILDREN WITH DIPG: A SINGLE-CENTER EXPERIENCE WITH 82 CASES
por: Lai, Mingyao, et al.
Publicado: (2020)

Are hypothalamic- pituitary (HP) axis deficiencies after whole brain radiotherapy (WBRT) of relevance for adult cancer patients? – a systematic review of the literature
por: Mehta, P., et al.
Publicado: (2019)

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
por: Tang, Jun-Hai, et al.
Publicado: (2019)

Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines
por: Lombardi, Francesca, et al.
Publicado: (2022)

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
por: Oike, Takahiro, et al.
Publicado: (2013)

Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis
por: Zhao, Qian, et al.
Publicado: (2016)

WBRT for brain metastases from non-small cell lung cancer: for whom and when?—Contemporary point of view
por: Sas-Korczynska, Beata, et al.
Publicado: (2021)

Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
por: Caraglia, M, et al.
Publicado: (2011)

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017)

The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
por: de Pádua Covas Lage, Luís Alberto, et al.
Publicado: (2022)

Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol
por: Chia, Brendan Seng Hup, et al.
Publicado: (2020)

Intensity-modulated radiation therapy combined with concomitant temozolomide for brain metastases from lung adenocarcinoma
por: Li, Jinli, et al.
Publicado: (2018)

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases – results and lessons learnt
por: Gupta, Avinash, et al.
Publicado: (2016)

Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report
por: Urso, Gaetano, et al.
Publicado: (2022)

Reduced-dose WBRT combined with SRS for 1–4 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control
por: Nakano, Toshimichi, et al.
Publicado: (2022)

RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM)
por: Tomé, Wolfgang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1i0akvjjshqm99ni57jpenbm6a